Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReCALL: Risk Stratified Treatment for Relapsed Childhood Acute Lymphoblastic Leukemia
NCT05827549Phase 2Recruiting
- Start
- Apr 2024
- Primary completion
- Dec 2032
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) (4 arms). Primary endpoint: Safety and Efficacy at 9 years. Started Apr 2024; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05827549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05827549.